We provide you with 20 years of free, institutional-grade data for STSA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of STSA. Explore the full financial landscape of STSA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Satsuma Pharmaceuticals, Inc(NASDAQ:STSA) 
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in AS...
Website: http://www.satsumarx.com
Founded: 2016
IPO Price: $15 (Sep 13, 2019)
Full Time Employees: 17
CEO: John A. Kollins
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about STSA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.